Hematopoietic cell transplantation in first complete remission versus early relapse

Best Practice & Research. Clinical Haematology
Frederick R Appelbaum, S Frieda Pearce

Abstract

Although data from a number of clinical trials can help guide the choice, the decision of whether patients with acute myeloid leukemia (AML) should undergo transplantation while in first remission or should have transplantation withheld until relapse is a particularly difficult one. Current data suggest that patients with AML and unfavorable cytogenetics should undergo allogeneic transplantation while in first remission if at all possible. Patients with AML and good risk cytogenetics can probably forgo transplantation until after first relapse. For patients with intermediate risk disease, the decision of transplantation during first remission versus waiting until first relapse is particularly difficult and should be made only after considering additional individual risk factors. If the decision is made to delay transplantation until first relapse, there are additional steps that physicians should take to ensure that salvage transplantation is possible, including identifying the source of hematopoietic stem cells in advance of relapse and developing a careful monitoring plan for the patient while in first remission.

Citations

Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B WalterJohn M Pagel
May 20, 2009·Future Oncology·Cortney V Jones, Edward A Copelan
Apr 16, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mehdi HamadaniEdward A Copelan
Jul 10, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M FeyUNKNOWN ESMO Guidelines Working Group
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Raya MawadJohn M Pagel
Oct 7, 2011·Cancer Control : Journal of the Moffitt Cancer Center·Mehdi HamadaniMohamed A Kharfan-Dabaja

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.